Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Oct 09, 2024 Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV Sep 26, 2024 Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update Sep 17, 2024 Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025 Sep 09, 2024 Theratechnologies to Present at Upcoming Investor Conferences in September Jul 10, 2024 Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 Jun 26, 2024 Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update May 23, 2024 Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors May 09, 2024 Theratechnologies Reports on its Annual Meeting of Shareholders May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 11 - 20 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Oct 09, 2024 Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
Sep 26, 2024 Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Sep 17, 2024 Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
Jul 10, 2024 Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Jun 26, 2024 Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
May 23, 2024 Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
